A clinical trial from MD Anderson Cancer Center reported the first oncologic outcomes for the omission of breast surgery using a vacuum-assisted biopsy (VAB) performed after NST in patients with strict inclusion criteria (cT1-2, cN0-1, triple-negative or HER2-positive breast cancers, residual lesion < 2 cm on imaging after NST). This evidence concerns the gene ERBB2 and breast cancer.